<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Chieffo, Alaide</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">TAVI with Balloon and Self-expandable Devices: Results from the Milan Registry</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Transcatheter aortic valve implantation (TAVI) is a viable treatment option for high-risk surgical patients with severe symptomatic aortic stenosis (AS). The SAPIEN XT™ (SXT) and CoreValve® with AccuTrak™ delivery system (MCVAT) are new generation devices currently available in Europe for transfemoral TAVI. To date, no prospective comparisons between these 2 devices have been undertaken. The objectives of this study were to assess the overall clinical outcomes of TAVI and to compare the SXT versus MCVAT devices in a nonrandomized registry population.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>